Sarepta prepares to present new data on Duchenne and limb-girdle muscular dystrophy gene therapy programs this week.
Rare Therapeutics will specifically advance gene therapies for extremely rare diseases with a goal of making them accessible globally.
10h
Gene Therapy Market Size to Worth USD 58.87 Billion Rising at 20% CAGR by 2034 | Towards Healthcare
The gene therapy market size is calculated at USD 11.4 billion in 2025 and is expected to reach around USD 58.87 billion by 2034, growing at a CAGR of 20% for the forecasted period.Ottawa, Oct. 08, ...
The country’s top drugmakers are set to meet in early December at the Four Seasons hotel in Georgetown with Donald Trump Jr.
In a setback for Sarepta Therapeutics, a New York panel has voted unanimously to recommend the state Medicaid program pause ...
Stocktwits on MSN
Why Sarepta Therapeutics Stock Is Rising Nearly 5% Premarket
Shares of Sarepta Therapeutics rose nearly 5% in early premarket trading on Wednesday as the company prepared to present new ...
Enzyme Replacement Therapy (ERT) generated over US$ 46 billion in 2024, driven by established treatments for Gaucher disease, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback